BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569-77; quiz 578. [PMID: 22158026 DOI: 10.1038/ajg.2011.425] [Cited by in Crossref: 406] [Cited by in F6Publishing: 387] [Article Influence: 40.6] [Reference Citation Analysis]
Number Citing Articles
1 Xiao S, Hu Z, He Y, Jin H, Yang Y, Chen L, Chen Q, Luo Q, Liu J. Enhancement Effect of Microbubble-Enhanced Ultrasound in Microwave Ablation in Rabbit VX2 Liver Tumors. Biomed Res Int 2020;2020:3050148. [PMID: 32090074 DOI: 10.1155/2020/3050148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RS, Diniz MA, Alves VA, D’Albuquerque LAC, Carrilho FJ. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival. World J Gastroenterol 2014; 20(6): 1585-1593 [PMID: 24587635 DOI: 10.3748/wjg.v20.i6.1585] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
3 Hiraoka A, Otsuka Y, Kawasaki H, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Mori I, Hiasa Y, Michitaka K. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2018;33:1271-6. [PMID: 29193248 DOI: 10.1111/jgh.14058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
4 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1001] [Article Influence: 526.7] [Reference Citation Analysis]
5 Kim CG, Lee HW, Choi HJ, Lee JI, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med. 2019;8:5023-5032. [PMID: 31290618 DOI: 10.1002/cam4.2417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
6 Beyer LP, Lürken L, Verloh N, Haimerl M, Michalik K, Schaible J, Stroszczynski C, Wiggermann P. Stereotactically navigated percutaneous microwave ablation (MWA) compared to conventional MWA: a matched pair analysis. Int J Comput Assist Radiol Surg 2018;13:1991-7. [PMID: 29728899 DOI: 10.1007/s11548-018-1778-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
7 Nishikawa H, Osaki Y. Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2014;44:149-158. [PMID: 23819582 DOI: 10.1111/hepr.12194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
8 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 981] [Article Influence: 188.2] [Reference Citation Analysis]
9 Lin CC, Cheng YT, Chen M WT, Lin SM. The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. Liver Cancer 2016;5:8-20. [PMID: 26989656 DOI: 10.1159/000367755] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
10 Tomonari A, Tsuji K, Yamazaki H, Aoki H, Kang J, Kodama Y, Sakurai Y, Maguchi H. Feasibility of the virtual needle tracking system for percutaneous radiofrequency ablation of hepatocellular carcinoma: Virtual needle tracking for RFA. Hepatol Res 2013;43:1352-5. [DOI: 10.1111/hepr.12096] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
11 Zhang B, Moser MA, Zhang EM, Luo Y, Zhang W. Numerical analysis of the relationship between the area of target tissue necrosis and the size of target tissue in liver tumours with pulsed radiofrequency ablation. Int J Hyperthermia 2015;31:715-25. [PMID: 26360111 DOI: 10.3109/02656736.2015.1058429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
12 Mcpartlin AJ, Dawson LA. Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. The Cancer Journal 2016;22:296-301. [DOI: 10.1097/ppo.0000000000000201] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9-18. [PMID: 27574587 DOI: 10.2147/jhc.s101448] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
14 Sethi S, Sahoo AK, Ganesh V, Trehan C. An unusual cause of right ventricular wall rupture during radiofrequency ablation of hepatocellular carcinoma. Saudi J Anaesth 2018;12:492-4. [PMID: 30100858 DOI: 10.4103/sja.SJA_731_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Yang W, Varghese T, Ziemlewicz T, Alexander M, Lubner M, Hinshaw JL, Wells S, Lee FT Jr. Delineation of Post-Procedure Ablation Regions with Electrode Displacement Elastography with a Comparison to Acoustic Radiation Force Impulse Imaging. Ultrasound Med Biol 2017;43:1953-62. [PMID: 28595851 DOI: 10.1016/j.ultrasmedbio.2017.04.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
16 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kim HJ, Lee HK, Cho JH. Comparison between the treatment area of electrode used for radiofrequency ablation of liver cancer focusing on 15G cooled-tip and CWT electrode. Pak J Med Sci 2016;32:555-8. [PMID: 27375688 DOI: 10.12669/pjms.323.8538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, Plastaras JP, Metz JM, Both S, Apisarnthanarax S. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. Pract Radiat Oncol. 2015;5:209-218. [PMID: 25703530 DOI: 10.1016/j.prro.2015.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
19 Lee DH, Lee JM, Lee JY, Kim SH, Han JK, Choi BI. Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis. Cardiovasc Intervent Radiol 2014;37:705-15. [PMID: 23912493 DOI: 10.1007/s00270-013-0708-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
20 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
21 Ma D, Gao X, Liu Z, Lu X, Ju H, Zhang N. Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Cell Prolif 2020;53:e12795. [PMID: 32722884 DOI: 10.1111/cpr.12795] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
22 Song KD, Lim HK, Rhim H, Lee MW, Kang TW, Paik YH, Kim JM, Joh JW. Hepatic resection vs percutaneous radiofrequency ablation of hepatocellular carcinoma abutting right diaphragm. World J Gastrointest Oncol 2019; 11(3): 227-237 [PMID: 30918595 DOI: 10.4251/wjgo.v11.i3.227] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
23 Kuo HT, Que J, Lin LC, Yang CC, Koay LB, Lin CH. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e9249. [PMID: 29390360 DOI: 10.1097/MD.0000000000009249] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
24 Zhang N, Ma D, Wang L, Zhu X, Pan Q, Zhao Y, Zhu W, Zhou J, Wang L, Chai Z, Ao J, Sun H, Tang Z. Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3. J Cancer 2017;8:3742-54. [PMID: 29151962 DOI: 10.7150/jca.20816] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
25 Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc. 2014;28:3429-3434. [PMID: 24935203 DOI: 10.1007/s00464-014-3617-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 8.3] [Reference Citation Analysis]
26 Zhang B, Moser MA, Zhang EM, Luo Y, Liu C, Zhang W. A review of radiofrequency ablation: Large target tissue necrosis and mathematical modelling. Phys Med 2016;32:961-71. [PMID: 27461969 DOI: 10.1016/j.ejmp.2016.07.092] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 8.6] [Reference Citation Analysis]
27 Kudo A, Shinoda M, Ariizumi S, Kumamoto T, Katayama M, Otsubo T, Endo I, Kitagawa Y, Tanabe M, Yamamoto M; Association for Clinical Research on Surgery Group. Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402. J Cancer Res Clin Oncol 2020;146:2949-56. [PMID: 32462296 DOI: 10.1007/s00432-020-03270-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 90.0] [Reference Citation Analysis]
29 Cheng J, Wang W, Zhang Y, Liu X, Li M, Wu Z, Liu Z, Lv Y, Wang B. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One. 2014;9:e87011. [PMID: 24498011 DOI: 10.1371/journal.pone.0087011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
30 Sato M, Tateishi R, Yasunaga H, Matsui H, Fushimi K, Ikeda H, Yatomi Y, Koike K. Association between hospital volume and in-hospital mortality following radiofrequency ablation for hepatocellular carcinoma. BJS Open 2017;1:50-4. [PMID: 29951606 DOI: 10.1002/bjs5.9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
31 Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol. 2014;25:1691-705.e4. [PMID: 25442132 DOI: 10.1016/j.jvir.2014.08.027] [Cited by in Crossref: 253] [Cited by in F6Publishing: 243] [Article Influence: 36.1] [Reference Citation Analysis]
32 Díaz-González Á, Vilana R, Bianchi L, García-Criado Á, Rimola J, Rodríguez de Lope C, Ferrer J, Ayuso C, Da Fonseca LG, Reig M, Forner A. Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. J Vasc Interv Radiol 2020;31:710-9. [PMID: 31685360 DOI: 10.1016/j.jvir.2019.06.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
33 Imai K, Beppu T, Chikamoto A, Doi K, Okabe H, Hayashi H, Nitta H, Ishiko T, Takamori H, Baba H. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43:853-864. [PMID: 23281579 DOI: 10.1111/hepr.12035] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
34 Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81-87. [PMID: 30773192 DOI: 10.1016/j.radonc.2018.12.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
35 Chan KS, Thng CB, Chan YH, Shelat VG. Outcomes of Gas-Forming Pyogenic Liver Abscess Are Comparable to Non-Gas-Forming Pyogenic Liver Abscess in the Era of Multi-Modal Care: A Propensity Score Matched Study. Surg Infect (Larchmt). 2020;. [PMID: 32216699 DOI: 10.1089/sur.2019.278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K, Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. Liver Cancer. 2020;9:50-62. [PMID: 32071909 DOI: 10.1159/000502744] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
37 Wang K, Li Y, Wang X, Jiao J, Li Y, Gu W, Liang X. Automatic Time-Resolved Fluorescence Immunoassay of Serum Alpha Fetoprotein-L3 Variant via LCA Magnetic Cationic Polymeric Liposomes Improves the Diagnostic Accuracy of Liver Cancer. Int J Nanomedicine 2020;15:4933-41. [PMID: 32764926 DOI: 10.2147/IJN.S242527] [Reference Citation Analysis]
38 Zhang L, Wang J, Jiang J, Zhang M, Shen J. CTLA-4 Blockade Suppresses Progression of Residual Tumors and Improves Survival After Insufficient Radiofrequency Ablation in a Subcutaneous Murine Hepatoma Model. Cardiovasc Intervent Radiol 2020;43:1353-61. [PMID: 32607616 DOI: 10.1007/s00270-020-02505-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Chen M, Zhang F, Song J, Weng Q, Li P, Li Q, Qian K, Ji H, Pietrini S, Ji J, Yang X. Image-Guided Peri-Tumoral Radiofrequency Hyperthermia-Enhanced Direct Chemo-Destruction of Hepatic Tumor Margins. Front Oncol 2021;11:593996. [PMID: 34235070 DOI: 10.3389/fonc.2021.593996] [Reference Citation Analysis]
40 Yoo J, Lee MW, Lee DH, Lee JH, Han JK. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int 2020;40:1189-200. [PMID: 32056353 DOI: 10.1111/liv.14406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
41 Yamashita S, Aoki T, Inoue Y, Kaneko J, Sakamoto Y, Sugawara Y, Hasegawa K, Kokudo N. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Surgery 2015;157:463-72. [DOI: 10.1016/j.surg.2014.10.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
42 Minami T, Tateishi R, Shiina S, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Yoshida H, Koike K. Spontaneous clearance of serum hepatitis C virus RNA during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis C: Spontaneous clearance of hepatitis C virus. Hepatol Res 2014;44:E32-7. [DOI: 10.1111/hepr.12203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
43 Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int. 2012;32:1434-1442. [PMID: 22712520 DOI: 10.1111/j.1478-3231.2012.02838.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
44 Chen R, Gan Y, Ge N, Chen Y, Ma H, Wang Y, Zhang B, Wang Y, Ye S, Luo J, Ren Z. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching: TACE versus RFA for early HCC. Journal of Gastroenterology and Hepatology 2016;31:442-9. [DOI: 10.1111/jgh.13077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
45 Zeng J, Cai X, Hao X, Huang F, He Z, Sun H, Lu Y, Lei J, Zeng W, Liu Y, Luo R. LncRNA FUNDC2P4 down-regulation promotes epithelial-mesenchymal transition by reducing E-cadherin expression in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Int J Hyperthermia 2018;34:802-11. [PMID: 29295626 DOI: 10.1080/02656736.2017.1422030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
46 Ziemlewicz TJ, Wells SA, Lubner MG, Brace CL, Lee FT Jr, Hinshaw JL. Hepatic Tumor Ablation. Surg Clin North Am 2016;96:315-39. [PMID: 27017867 DOI: 10.1016/j.suc.2015.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
47 Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther 2020;20:63-74. [PMID: 31910040 DOI: 10.1080/14737140.2020.1712198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
48 Song KD, Lee MW, Park HJ, Cha DI, Kang TW, Lee J, Moon JY, Rhim H. Hepatic radiofrequency ablation: in vivo and ex vivo comparisons of 15-gauge (G) and 17-G internally cooled electrodes. Br J Radiol 2015;88:20140497. [PMID: 25882688 DOI: 10.1259/bjr.20140497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Shousha HI, Fouad R, Elbaz TM, Sabry D, Mahmoud Nabeel M, Hosni Abdelmaksoud A, Mahmoud Elsharkawy A, Soliman ZA, Habib G, Abdelaziz AO. Predictors of recurrence and survival of hepatocellular carcinoma: A prospective study including transient elastography and cancer stem cell markers. Arab J Gastroenterol 2020;21:95-101. [PMID: 32439234 DOI: 10.1016/j.ajg.2020.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Bouda D, Lagadec M, Alba CG, Barrau V, Dioguardi Burgio M, Moussa N, Vilgrain V, Ronot M. Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly: Imaging of HCC After Thermal Ablation. J Magn Reson Imaging 2016;44:1070-90. [DOI: 10.1002/jmri.25369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
51 Giannini EG. Thrombocytopenia in patients with chronic liver disease: what's in a name? Dig Dis Sci 2013;58:299-301. [PMID: 23086124 DOI: 10.1007/s10620-012-2450-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. Placement of a Sodium Hyaluronate Solution onto the Liver Surface as a Supportive Procedure for Radiofrequency Ablation of Hepatocellular Carcinomas Located on the Liver Surface: A Preliminary Report. Journal of Vascular and Interventional Radiology 2012;23:1639-1645.e1. [DOI: 10.1016/j.jvir.2012.08.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
53 Inoue T, Kudo M, Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology. 2013;84 Suppl 1:51-57. [PMID: 23428859 DOI: 10.1159/000345890] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
54 Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore) 2017;96:e5518. [PMID: 28099329 DOI: 10.1097/MD.0000000000005518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
55 Nakagawa H, Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol 2012; 18(31): 4071-4081 [PMID: 22919237 DOI: 10.3748/wjg.v18.i31.4071] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 80] [Article Influence: 9.8] [Reference Citation Analysis]
56 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
57 Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: local control rate and risk of peritoneal seeding at long-term follow-up. Clin Radiol 2013;68:e641-51. [PMID: 23973161 DOI: 10.1016/j.crad.2013.07.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
58 Lee MW, Rhim H, Cha DI, Kim YJ, Lim HK. Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1-3 cm): value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol. 2013;24:958-965. [PMID: 23796082 DOI: 10.1016/j.jvir.2013.04.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
59 Lee S, Kim H, Ji Y, Cho B, Kim SS, Jung J, Kwak J, Park JH, Lee SW, Kim JH, Yoon SM. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration. Sci Rep 2018;8:16224. [PMID: 30385839 DOI: 10.1038/s41598-018-34676-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Pohlman RM, Varghese T. Dictionary Representations for Electrode Displacement Elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2018;65:2381-9. [PMID: 30296219 DOI: 10.1109/TUFFC.2018.2874181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
61 Imai K, Beppu T, Chikamoto A, Mima K, Okabe H, Hayashi H, Nitta H, Ishiko T, Baba H. Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy: Salvage for local recurrence of HCC. Hepatol Res 2014;44:E335-45. [DOI: 10.1111/hepr.12313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
62 Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC. Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore). 2015;94:e1929. [PMID: 26512620 DOI: 10.1097/md.0000000000001929] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
63 Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2020;9:382-396. [PMID: 32999866 DOI: 10.1159/000507022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
64 Kim JW, Shin SS, Heo SH, Hong JH, Lim HS, Seon HJ, Hur YH, Park CH, Jeong YY, Kang HK. Ultrasound-Guided Percutaneous Radiofrequency Ablation of Liver Tumors: How We Do It Safely and Completely. Korean J Radiol 2015;16:1226-39. [PMID: 26576111 DOI: 10.3348/kjr.2015.16.6.1226] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
65 Jayant K, Sodergren MH, Reccia I, Kusano T, Zacharoulis D, Spalding D, Pai M, Jiao LR, Huang KW. A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique. Cancers (Basel) 2018;10:E428. [PMID: 30413094 DOI: 10.3390/cancers10110428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
66 Tateishi R, Fujiwara N. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 195-224. [DOI: 10.1007/978-3-030-21540-8_10] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; LiverHope Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol 2021;74:200-19. [PMID: 32896580 DOI: 10.1016/j.jhep.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
68 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 665] [Article Influence: 165.3] [Reference Citation Analysis]
69 Zhang R, Lin XH, Ma M, Chen J, Chen J, Gao DM, Cui JF, Chen RX. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition. J Transl Med 2018;16:302. [PMID: 30400797 DOI: 10.1186/s12967-018-1676-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
70 Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, Koike K. Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E447. [PMID: 30445800 DOI: 10.3390/cancers10110447] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 18.0] [Reference Citation Analysis]
71 Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019;157:1253-1263.e2. [PMID: 31374215 DOI: 10.1053/j.gastro.2019.07.040] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 26.5] [Reference Citation Analysis]
72 Hermida M, Cassinotto C, Piron L, Assenat E, Pageaux GP, Escal L, Pierredon-Foulongne MA, Verzilli D, Jaber S, Guiu B. Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy. Int J Hyperthermia 2018;35:90-6. [PMID: 29923441 DOI: 10.1080/02656736.2018.1477206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
73 Francica G, Meloni MF, de Sio I, Smolock AR, Brace CL, Iadevaia MD, Santambrogio R, Sironi S, Scaglione M, Lee Jr. FT. Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: Safety and efficacy. European Journal of Radiology 2016;85:739-43. [DOI: 10.1016/j.ejrad.2016.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
74 Kim YS, Lim HK, Rhim H, Lee MW. Ablation of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014;28:897-908. [PMID: 25260316 DOI: 10.1016/j.bpg.2014.08.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
75 Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:2-6. [PMID: 28261590 DOI: 10.21037/hbsn.2016.09.07] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
76 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Takami Y, Eguchi S, Tateishi M, Ryu T, Mikagi K, Wada Y, Saitsu H. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment. Hepatol Int 2016;10:799-806. [PMID: 26846471 DOI: 10.1007/s12072-016-9704-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
78 Di Costanzo GG, Tortora R, D’Adamo G, De Luca M, Lampasi F, Addario L, Galeota Lanza A, Picciotto FP, Tartaglione MT, Cordone G. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol. 2015;30:559-565. [PMID: 25251043 DOI: 10.1111/jgh.12791] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
79 Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013;29:558-568. [PMID: 23937321 DOI: 10.3109/02656736.2013.821528] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
80 Nishigori S, Numata K, Irie K, Fukuda H, Chuma M, Maeda S. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. J Med Ultrason (2001) 2018;45:405-15. [PMID: 29362966 DOI: 10.1007/s10396-018-0861-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
81 Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21:1543-1552. [PMID: 26457885 DOI: 10.1002/lt.24356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
82 Viganò L, Laurenzi A, Solbiati L, Procopio F, Cherqui D, Torzilli G. Open Liver Resection, Laparoscopic Liver Resection, and Percutaneous Thermal Ablation for Patients with Solitary Small Hepatocellular Carcinoma (≤30 mm): Review of the Literature and Proposal for a Therapeutic Strategy. Dig Surg 2018;35:359-71. [PMID: 29890512 DOI: 10.1159/000489836] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
83 Saviano A, Iezzi R, Giuliante F, Salvatore L, Mele C, Posa A, Ardito F, De Gaetano AM, Pompili M; HepatoCATT Study Group. Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017;28:1512-1519. [PMID: 28734848 DOI: 10.1016/j.jvir.2017.06.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
84 Makino Y, Imai Y, Igura T, Hori M, Fukuda K, Sawai Y, Kogita S, Ohama H, Matsumoto Y, Nakahara M, Zushi S, Kurokawa M, Isotani K, Takamura M, Fujita N, Murakami T. Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression: Evaluation of RFA using CT fusion image. Hepatol Res 2013;43:950-8. [DOI: 10.1111/hepr.12049] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
85 Pohlman RM, Varghese T. Physiological Motion Reduction Using Lagrangian Tracking for Electrode Displacement Elastography. Ultrasound Med Biol 2020;46:766-81. [PMID: 31806499 DOI: 10.1016/j.ultrasmedbio.2019.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine. 2015;73:245-252. [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
87 Subramanian S, Schmidt DT, Rao MB, Mast TD. Dependence of ultrasound echo decorrelation on local tissue temperature during ex vivo radiofrequency ablation. Phys Med Biol 2016;61:2356-71. [PMID: 26943026 DOI: 10.1088/0031-9155/61/6/2356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
88 Gu JH, Zhu L, Jiang TA. Quantitative Ultrasound Elastography Methods in Focal Liver Lesions Including Hepatocellular Carcinoma: From Diagnosis to Prognosis. Ultrasound Q 2021;37:90-6. [PMID: 34057911 DOI: 10.1097/RUQ.0000000000000491] [Reference Citation Analysis]
89 Sempokuya T, Wong LL. Ten-year survival and recurrence of hepatocellular cancer. Hepatoma Res 2019;5:38. [PMID: 31701016 DOI: 10.20517/2394-5079.2019.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
90 Yang W, Yan K, Wu GX, Wu W, Fu Y, Lee JC, Zhang ZY, Wang S, Chen MH. Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes. World J Gastroenterol 2015; 21(5): 1554-1566 [PMID: 25663774 DOI: 10.3748/wjg.v21.i5.1554] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
91 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 12.4] [Reference Citation Analysis]
92 Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, Dev A, Rode A, Bailey M, Cheung W. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol. 2015;50:567-576. [PMID: 25615260 DOI: 10.3109/00365521.2014.953572] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
93 Wang Z, Han YJ, Huang S, Wang M, Zhou WL, Li HS, Wang QS, Wu HB. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids 2018;50:309-20. [PMID: 29204748 DOI: 10.1007/s00726-017-2517-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
94 Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J Gastrointest Surg. 2013;17:719-729. [PMID: 23404173 DOI: 10.1007/s11605-013-2164-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
95 Sohn W, Choi MS, Cho JY, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors. Gut Liver. 2014;8:543-551. [PMID: 25071073 DOI: 10.5009/gnl13356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
96 Janikashvili N, Jayant K, Kikodze N, Mazmishvili K, Pantsulaia I, Sandhu B, Podda M, Iobadze M, Azrumelashvili T, Mizandari M, Habib N, Chikovani T. Immunomodulatory Changes Following Isolated RF Ablation in Colorectal Liver Metastases: A Case Report. Medicines (Basel) 2019;6:E56. [PMID: 31085982 DOI: 10.3390/medicines6020056] [Reference Citation Analysis]
97 Lee LH, Hwang JI, Cheng YC, Wu CY, Lee SW, Yang SS, Yeh HZ, Chang CS, Lee TY. Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS One 2017;12:e0169655. [PMID: 28068369 DOI: 10.1371/journal.pone.0169655] [Reference Citation Analysis]
98 Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. Perivascular versus nonperivascular small HCC treated with percutaneous RF ablation: retrospective comparison of long-term therapeutic outcomes. Radiology. 2014;270:888-899. [PMID: 24475820 DOI: 10.1148/radiol.13130753] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
99 Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, Dinniwell R, Kim J, Cho C, Ringash J, Wong R, Cuneo K, Feng M, Lawrence TS, Dawson LA. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer 2020;134:41-51. [PMID: 32460180 DOI: 10.1016/j.ejca.2020.04.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
100 Morimoto N, Isoda N, Takaoka Y, Hirosawa T, Watanabe S, Otake T, Murayama K, Fujieda T, Tsukui M, Miyata N, Ono K, Yamaguchi S, Yamamoto H. Short-Term Results of Laparoscopic Radiofrequency Ablation Using a Multipolar System for Localized Hepatocellular Carcinoma. Liver Cancer 2017;6:137-45. [PMID: 28275580 DOI: 10.1159/000450925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
101 Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
102 Ma QP, Xu EJ, Zeng QJ, Su ZZ, Tan L, Chen JX, Zheng RQ, Li K. Intraprocedural computed tomography/magnetic resonance-contrast-enhanced ultrasound fusion imaging improved thermal ablation effect of hepatocellular carcinoma: Comparison with conventional ultrasound. Hepatol Res 2019;49:799-809. [PMID: 30907477 DOI: 10.1111/hepr.13336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Park SJ, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kang HJ, Yoon JH, Lee DH, Kim SH, Lee JY, Lee JM. Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. Liver Cancer 2021;10:72-81. [PMID: 33708641 DOI: 10.1159/000512338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6:325-336. [PMID: 29234636 DOI: 10.1159/000479984] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 16.0] [Reference Citation Analysis]
105 Takuma Y, Shota I, Miyatake H, Uematsu S, Okamoto R, Araki Y, Takabatake H, Morimoto Y, Yamamoto H. Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. Intern Med 2018;57:457-68. [PMID: 29151504 DOI: 10.2169/internalmedicine.9064-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
106 Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Wang H, Gao X, Chang X, An L, Li H, Chen Y, Hu KQ, Yang Y. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLoS One. 2015;10:e0123065. [PMID: 25849963 DOI: 10.1371/journal.pone.0123065] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
107 Qiu S, Jiao LR. Improving detection combined with targeted therapy for small hepatocellular carcinoma. Ann Transl Med 2019;7:S4. [PMID: 31032285 DOI: 10.21037/atm.2019.01.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Drobczyński S, Prorok K, Tamarov K, Duś-szachniewicz K, Lehto V, Bednarkiewicz A. Toward Controlled Photothermal Treatment of Single Cell: Optically Induced Heating and Remote Temperature Monitoring In Vitro through Double Wavelength Optical Tweezers. ACS Photonics 2017;4:1993-2002. [DOI: 10.1021/acsphotonics.7b00375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
109 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
110 Mikami S, Tateishi R, Akahane M, Asaoka Y, Kondo Y, Goto T, Shiina S, Yoshida H, Koike K. Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience. J Vasc Interv Radiol. 2012;23:1269-1275. [PMID: 22999746 DOI: 10.1016/j.jvir.2012.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
111 Yang W, Yan K, Goldberg SN, Ahmed M, Lee JC, Wu W, Zhang ZY, Wang S, Chen MH. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol 2016; 22(10): 2993-3005 [PMID: 26973395 DOI: 10.3748/wjg.v22.i10.2993] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
112 Zhang D, Liu Z, Yin X, Qi X, Lu B, Liu Y, Hou J. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis. Int J Biol Markers 2018;33:266-74. [PMID: 29658364 DOI: 10.1177/1724600818760234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Tajiri K, Baba H, Kawai K, Minemura M, Yasumura S, Takahara T, Sugiyama T. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016;31:1291-1299. [PMID: 26729319 DOI: 10.1111/jgh.13287] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
114 Zhang B, Moser MAJ, Zhang EM, Luo Y, Zhang W. A new approach to feedback control of radiofrequency ablation systems for large coagulation zones. International Journal of Hyperthermia 2016;33:367-77. [DOI: 10.1080/02656736.2016.1263365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
115 Rich NE, Yopp AC, Singal AG. Medical Management of Hepatocellular Carcinoma. JOP 2017;13:356-64. [DOI: 10.1200/jop.2017.022996] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
116 Fu X, Mao L, Tang M, Yan X, Qiu Y, He J, Zhou T. Gross classification of solitary small hepatocellular carcinoma on preoperative computed tomography: Prognostic significance after radiofrequency ablation. Hepatol Res. 2016;46:298-305. [PMID: 26041379 DOI: 10.1111/hepr.12540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
117 Yoon JH, Goo YJ, Lim CJ, Choi SK, Cho SB, Shin SS, Jun CH. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2020; 26(32): 4833-4845 [PMID: 32921960 DOI: 10.3748/wjg.v26.i32.4833] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
118 Shimizu M, Shirakami Y, Hanai T, Imai K, Suetsugu A, Takai K, Shiraki M, Moriwaki H. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Mol Nutr Food Res 2014;58:124-35. [PMID: 24273224 DOI: 10.1002/mnfr.201300538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
119 Jiang X, Kanda T, Tanaka T, Wu S, Nakamoto S, Imazeki F, Yokosuka O. Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines. Immunol Lett 2013;152:8-15. [PMID: 23578665 DOI: 10.1016/j.imlet.2013.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
120 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
121 Nault J, Sutter O, Nahon P, Ganne-carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. Journal of Hepatology 2018;68:783-97. [DOI: 10.1016/j.jhep.2017.10.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 33.0] [Reference Citation Analysis]
122 Meng F, Zhang H, Peng H, Lu S. Comparison of 10-Year Survival Outcomes for Early Single Hepatocellular Carcinoma following Different Treatments. Biomed Res Int 2021;2021:6638117. [PMID: 34150908 DOI: 10.1155/2021/6638117] [Reference Citation Analysis]
123 Kao WY, Su CW, Chiou YY, Chiu NC, Liu CA, Fang KC, Huo TI, Huang YH, Chang CC, Hou MC, Lin HC, Wu JC. Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology. 2017;285:670-680. [PMID: 28562211 DOI: 10.1148/radiol.2017162382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
124 Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. [PMID: 27467945 DOI: 10.1080/2162402x.2015.1129483] [Cited by in Crossref: 77] [Cited by in F6Publishing: 52] [Article Influence: 15.4] [Reference Citation Analysis]
125 Poggi G, Tosoratti N, Montagna B, Picchi C. Microwave ablation of hepatocellular carcinoma. World J Hepatol 2015; 7(25): 2578-2589 [PMID: 26557950 DOI: 10.4254/wjh.v7.i25.2578] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 9.7] [Reference Citation Analysis]
126 Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location. AJR Am J Roentgenol. 2012;199:1393-1401. [PMID: 23169736 DOI: 10.2214/ajr.11.7850] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
127 Ippolito D, Trattenero C, Talei Franzesi C, Casiraghi A, Lombardi S, Vacirca F, Corso R, Sironi S. Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid for Quantitative Assessment of Vascular Effects on Hepatocellular-Carcinoma Lesions Treated by Transarterial Chemoembolization or Radiofrequency Ablation. J Comput Assist Tomogr. 2016;40:692-700. [PMID: 27560010 DOI: 10.1097/rct.0000000000000427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
128 Huo TI, Liu PH, Ho SY. Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation. J Gastroenterol Hepatol 2020;35:2020. [PMID: 32476182 DOI: 10.1111/jgh.15126] [Reference Citation Analysis]
129 Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, Park JH, Kim SY, Shim JH, Kim KM, Lim YS, Lee HC, Yoon SM. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018;18:416. [PMID: 29653562 DOI: 10.1186/s12885-018-4340-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
130 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians 2012;62:394-9. [DOI: 10.3322/caac.21161] [Cited by in Crossref: 498] [Cited by in F6Publishing: 532] [Article Influence: 55.3] [Reference Citation Analysis]
132 Yamashita Y, Tsuijita E, Takeishi K, Ishida T, Ikegami T, Ezaki T, Maeda T, Utsunomiya T, Nagasue N, Shirabe K. Trends in surgical results of hepatic resection for hepatocellular carcinoma: 1,000 consecutive cases over 20 years in a single institution. Am J Surg. 2014;207:890-896. [PMID: 24144344 DOI: 10.1016/j.amjsurg.2013.07.028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
133 Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y. Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol 2018;2018:4756147. [PMID: 29974040 DOI: 10.1155/2018/4756147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
134 Yamamoto N, Okano K, Kushida Y, Deguchi A, Yachida S, Suzuki Y. Clinicopathology of recurrent hepatocellular carcinomas after radiofrequency ablation treated with salvage surgery. Hepatol Res. 2014;44:1062-1071. [PMID: 23957810 DOI: 10.1111/hepr.12223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
135 Ju JX, Zeng QJ, Xu EJ, He XQ, Tan L, Huang QN, Li K, Zheng RQ. Intraprocedural contrast-enhanced ultrasound-CT/MR fusion imaging assessment in HCC thermal ablation to reduce local tumor progression: compared with routine contrast-enhanced ultrasound. Int J Hyperthermia 2019;36:785-93. [PMID: 31431086 DOI: 10.1080/02656736.2019.1640899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
136 Fukuhara T, Aikata H, Hyogo H, Honda Y, Morio K, Morio R, Hatooka M, Kobayashi T, Naeshiro N, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Chayama K. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. Eur J Radiol 2015;84:1540-5. [PMID: 25979193 DOI: 10.1016/j.ejrad.2015.04.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
137 Xie L, Cao F, Qi H, Song Z, Shen L, Chen S, Hu Y, Chen C, Fan W. Efficacy and safety of CT-guided percutaneous thermal ablation for hepatocellular carcinoma adjacent to the second porta hepatis. International Journal of Hyperthermia 2019;36:1121-7. [DOI: 10.1080/02656736.2019.1684575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Zheng H, Xu C, Wang X, Li J, Zhao X, Qi J, Feng Y, Zhu Q. Microwave ablation shows similar survival outcomes compared with surgical resection for hepatocellular carcinoma between 3 and 5 cm. Int J Hyperthermia 2020;37:1345-53. [PMID: 33289415 DOI: 10.1080/02656736.2020.1849825] [Reference Citation Analysis]
139 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
140 Giannini EG, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Ten-Year Outcome of Radiofrequency Thermal Ablation for Hepatocellular Carcinoma: An Italian Experience. American Journal of Gastroenterology 2012;107:1588-9. [DOI: 10.1038/ajg.2012.250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
141 Park SI, Kim IJ, Lee SJ, Shin MW, Shin WS, Chung YE, Kim GM, Kim MD, Won JY, Lee do Y, Choi JS, Han KH. Angled Cool-Tip Electrode for Radiofrequency Ablation of Small Superficial Subcapsular Tumors in the Liver: A Feasibility Study. Korean J Radiol 2016;17:742-9. [PMID: 27587963 DOI: 10.3348/kjr.2016.17.5.742] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
142 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
143 Yao E, Chen J, Zhao X, Zheng Y, Wu X, Han F, Huang H, Liang P, Liu J, Wu F, Lin L. Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Biomed Res Int 2018;2018:5481909. [PMID: 29687004 DOI: 10.1155/2018/5481909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
144 Nault J, Nkontchou G, Nahon P, Grando V, Bourcier V, Barge S, Ziol M, Sellier N, Ganne-carrie N, Seror O. Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis. Ann Surg Oncol 2016;23:1906-15. [DOI: 10.1245/s10434-015-5064-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
145 Ho CM, Liang PC. Diaphragm perforation after radiofrequency ablation for liver malignancy. Oxf Med Case Reports 2014;2014:32. [PMID: 25988018 DOI: 10.1093/omcr/omu014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Asaoka Y, Tateishi R, Nakagomi R, Kondo M, Fujiwara N, Minami T, Sato M, Uchino K, Enooku K, Nakagawa H. Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma. PLoS One. 2014;9:e111662. [PMID: 25397677 DOI: 10.1371/journal.pone.0111662] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
147 Pang Q, Qu K, Bi JB, Liu SS, Zhang JY, Song SD, Lin T, Xu XS, Wan Y, Tai MH, Liu HC, Dong YF, Liu C. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World J Gastroenterol 2015; 21(25): 7895-7906 [PMID: 26167090 DOI: 10.3748/wjg.v21.i25.7895] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
148 Satiya J, Schwartz I, Tabibian JH, Kumar V, Girotra M. Ablative therapies for hepatic and biliary tumors: endohepatology coming of age. Transl Gastroenterol Hepatol 2020;5:15. [PMID: 32258519 DOI: 10.21037/tgh.2019.10.17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
149 Salati U, Barry A, Chou FY, Ma R, Liu DM. State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. Future Oncology 2017;13:1437-48. [DOI: 10.2217/fon-2017-0061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
150 De Bari B, Ozsahin M, Bize P, Boussaha T, Deplanque G, Wagner D, Bourhis J, Denys A. Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma? J Clin Oncol 2016;34:2798-9. [PMID: 27325861 DOI: 10.1200/JCO.2016.66.7196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
151 Chen Z, Zhao H, Qiao X, Yi C, Gao S, Gao W, Liu Z. Effect of Microbubble-Enhanced Ultrasound on Radiofrequency Ablation of Rabbit Liver. Ultrasound Med Biol 2018;44:1451-9. [PMID: 29685588 DOI: 10.1016/j.ultrasmedbio.2018.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Lee H, Kim JW, Hur YH, Shin SS, Heo SH, Cho SB, Kang YJ, Lim HS, Seon HJ, Jeong YY. Combined Therapy of Transcatheter Arterial Chemoembolization and Radiofrequency Ablation versus Surgical Resection for Single 2–3 cm Hepatocellular Carcinoma: A Propensity-Score Matching Analysis. Journal of Vascular and Interventional Radiology 2017;28:1240-1247.e3. [DOI: 10.1016/j.jvir.2017.05.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
153 Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
154 Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Wang H, Gao X, Chang X, An L, Chen Y, Yang Y. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases. Front Med 2015;9:63-71. [DOI: 10.1007/s11684-014-0342-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
155 Zhang B, Moser MA, Zhang EM, Luo Y, Zhang H, Zhang W. Study of the relationship between the target tissue necrosis volume and the target tissue size in liver tumours using two-compartment finite element RFA modelling. Int J Hyperthermia 2014;30:593-602. [PMID: 25430990 DOI: 10.3109/02656736.2014.984000] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
156 Lee DH, Lee JM. Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources. Korean J Radiol 2018;19:545-59. [PMID: 29962861 DOI: 10.3348/kjr.2018.19.4.545] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
157 Yuan ZG, Wang ZY, Xia MY, Li FZ, Li Y, Shen Z, Wang XZ. Comparison of diffusion kurtosis imaging versus diffusion weighted imaging in predicting the recurrence of early stage single nodules of hepatocellular carcinoma treated by radiofrequency ablation. Cancer Imaging 2019;19:30. [PMID: 31142356 DOI: 10.1186/s40644-019-0213-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
158 Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol 2014; 20(11): 2876-2887 [PMID: 24659879 DOI: 10.3748/wjg.v20.i11.2876] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
159 Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, Cantamessa A, Giorgio A, Scognamiglio U, Fornari F, Giangregorio F, Piscaglia F, Gualandi S, Caturelli E, Roselli P, Rapaccini GL, Pompili M. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis. 2013;45:336-341. [PMID: 23245589 DOI: 10.1016/j.dld.2012.10.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
160 Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo 2019;33:1411-20. [PMID: 31471386 DOI: 10.21873/invivo.11618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
161 Yuri Y, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy. J Cancer 2017;8:1507-16. [PMID: 28775769 DOI: 10.7150/jca.19175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
162 Zhang W, Luo E, Gan J, Song X, Bao Z, Zhang H, Chen M. Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound. World J Surg Oncol 2017;15:122. [PMID: 28679433 DOI: 10.1186/s12957-017-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
163 Honda K, Seike M, Oribe J, Endo M, Arakawa M, Syo H, Iwao M, Tokoro M, Nishimura J, Mori T, Yamashita T, Fukuchi S, Muro T, Murakami K. Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy. World J Hepatol 2016; 8(13): 597-604 [PMID: 27168872 DOI: 10.4254/wjh.v8.i13.597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
164 Chua JME, Lam YMP, Tan BS, Tay KH, Gogna A, Irani FG, Lo HGR, Too CW. Single-centre retrospective review of risk factors for local tumour progression and complications in radiofrequency ablation of 555 hepatic lesions. Singapore Med J 2019;60:188-92. [PMID: 31069400 DOI: 10.11622/smedj.2019036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
165 Sugimoto K, Oshiro H, Ogawa S, Honjo M, Hara T, Moriyasu F. Radiologic-pathologic correlation of three-dimensional shear-wave elastographic findings in assessing the liver ablation volume after radiofrequency ablation. World J Gastroenterol 2014; 20(33): 11850-11855 [PMID: 25206291 DOI: 10.3748/wjg.v20.i33.11850] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
166 Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim MJ, Lim YS, Lee HC, Jung J, Park JH, Kim JH, Kim SY, Yoon SM. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. J Gastroenterol Hepatol 2021;36:1962-70. [PMID: 33594690 DOI: 10.1111/jgh.15442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
168 Qiu J, Chen S, Wu H. Long-term outcomes after hepatic resection combined with radiofrequency ablation for initially unresectable multiple and bilobar liver malignancies. J Surg Res. 2014;188:14-20. [PMID: 24387841 DOI: 10.1016/j.jss.2013.11.1120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
169 Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R. Developing a Roadmap for Interventional Oncology. Oncologist 2018;23:1162-70. [PMID: 29959284 DOI: 10.1634/theoncologist.2017-0654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
170 Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol. 2018;3:89. [PMID: 30603725 DOI: 10.21037/tgh.2018.10.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
171 Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shiina S. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65:1272-1273. [PMID: 27524465 DOI: 10.1016/j.jhep.2016.07.043] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 11.8] [Reference Citation Analysis]
172 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
173 Knox JJ, Cleary SP, Dawson LA. Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. JCO 2015;33:1835-44. [DOI: 10.1200/jco.2014.60.1153] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
174 Lee ES, Lee JM, Kim KW, Lee IJ, Han JK, Choi BI. Evaluation of the in vivo efficiency and safety of hepatic radiofrequency ablation using a 15-G Octopus® in pig liver. Korean J Radiol 2013;14:194-201. [PMID: 23482995 DOI: 10.3348/kjr.2013.14.2.194] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
175 Kanogawa N, Ogasawara S, Chiba T, Saito T, Motoyama T, Suzuki E, Ooka Y, Tawada A, Kanda T, Mikami S. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197-1204. [PMID: 25682720 DOI: 10.1111/jgh.12925] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
176 Park HJ, Lee MW, Song KD, Cha DI, Rhim H, Kang TW, Lim S, Lim HK. Comparison of therapeutic efficacy and safety of radiofrequency ablation of hepatocellular carcinomas between internally cooled 15-G and 17-G single electrodes. Br J Radiol 2014;87:20130534. [PMID: 24646182 DOI: 10.1259/bjr.20130534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
177 Lee MW, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020;30:2391-400. [DOI: 10.1007/s00330-019-06575-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
178 Eriguchi T, Takeda A, Tateishi Y, Tsurugai Y, Sanuki N, Ebinuma H, Horita N. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021;51:813-22. [PMID: 33856722 DOI: 10.1111/hepr.13647] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
180 Sulaiman AS, Gani RA, Hasan I, Lesmana CRA, Kurniawan J, Jasirwan COM, Kalista KF, Nababan SHH, Aprilicia G, Lesmana LA. Overall Survival of Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation (RFA) Treatment: a Retrospective Cohort Study from Two Referral Hospitals in Indonesia. J Gastrointest Cancer 2021. [PMID: 34379264 DOI: 10.1007/s12029-021-00676-0] [Reference Citation Analysis]
181 Nakayama H, Takayama T, Okubo T, Higaki T, Midorikawa Y, Moriguchi M, Itoh A. Proposal of objective morphological classification system for hepatocellular carcinoma using preoperative multiphase computed tomography. J Gastroenterol. 2014;49:1430-1437. [PMID: 24240709 DOI: 10.1007/s00535-013-0908-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
182 Sato K, Taniki N, Kanazawa R, Shimizu M, Ishii S, Ohama H, Takawa M, Nagamatsu H, Imai Y, Shiina S. Efficacy and Safety of Deep Sedation in Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma. Adv Ther 2019;36:344-54. [PMID: 30607546 DOI: 10.1007/s12325-018-0865-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
183 Nishida N. Long-term prognosis and management of hepatocellular carcinoma after curative treatment. Clin Mol Hepatol 2020;26:480-3. [PMID: 32951413 DOI: 10.3350/cmh.2020.0208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
184 Wei CY, Chau GY, Chen PH, Liu CA, Huang YH, Huo TI, Hou MC, Lin HC, Su YH, Wu JC, Su CW. A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Sci Rep 2020;10:17259. [PMID: 33057213 DOI: 10.1038/s41598-020-74424-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Zhang L, Ge N, Chen Y, Xie X, Yin X, Gan Y, Zhang B, Zhang J, Chen R, Wang Y, Ye S, Ren Z. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0532-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
186 Tanaka Y, Tateishi R, Koike K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3070. [PMID: 30297672 DOI: 10.3390/ijms19103070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
187 Wang H, Cao Y, Hu K, Li Q, Yang Y, Wang L, Qin X, Qiao B, Cheng L, Li P, Dui W. Radiofrequency ablation triggers the migration of hepatocellular carcinoma cells by suppressing miR-148a-5p. Biol Chem 2020;401:985-94. [PMID: 32142478 DOI: 10.1515/hsz-2020-0130] [Reference Citation Analysis]
188 Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018;pii:S1542-3565(18)31394-6. [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
189 Mori Y, Tamai H, Shingaki N, Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Terada M, Ichinose M. Signal intensity of small hepatocellular carcinoma on apparent diffusion coefficient mapping and outcome after radiofrequency ablation: ADC mapping and outcome after RFA. Hepatol Res 2015;45:75-87. [DOI: 10.1111/hepr.12311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
190 Xu Y, Shen Q, Wang N, Wu PP, Huang B, Kuang M, Qian GJ. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer 2017;36:14. [PMID: 28103953 DOI: 10.1186/s40880-017-0183-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
191 Ding H, Su M, Zhu C, Wang L, Zheng Q, Wan Y. CT-guided versus laparoscopic radiofrequency ablation in recurrent small hepatocellular carcinoma against the diaphragmatic dome. Sci Rep 2017;7:44583. [PMID: 28291254 DOI: 10.1038/srep44583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
192 Wang Z, Yang G, Nie P, Fu J, Wang X, Liu D. Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models. PLoS One 2013;8:e74327. [PMID: 23977399 DOI: 10.1371/journal.pone.0074327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
193 Hermida M, Cassinotto C, Piron L, Aho-Glélé S, Guillot C, Schembri V, Allimant C, Jaber S, Pageaux GP, Assenat E, Guiu B. Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: Predictive Factors of Recurrence and Survival in Western Patients. Cancers (Basel) 2020;12:E313. [PMID: 32013112 DOI: 10.3390/cancers12020313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
194 Kinoshita A, Koike K, Nishino H. Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatr Gerontol Int 2017;17:189-201. [PMID: 26847184 DOI: 10.1111/ggi.12747] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
195 Lee LH, Hwang JI, Cheng YC, Wu CY, Lee SW, Yang SS, Yeh HZ, Chang CS, Lee TY. Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS One 2017;12:e0169655. [PMID: 28068369 DOI: 10.1371/journal.pone.0169655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
196 Lee S, Han S, Shim JH, Kim SY, Won HJ, Shin YM, Kim PN, An J, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1787-94.e1. [PMID: 26542708 DOI: 10.1016/j.jvir.2015.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
197 Nakagawa H. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. World J Hepatol 2015; 7(17): 2110-2118 [PMID: 26301053 DOI: 10.4254/wjh.v7.i17.2110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
198 Park J, Lee JM, Lee DH, Joo I, Yoon JH, Park JY, Klotz E. Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2017;40:873-83. [DOI: 10.1007/s00270-017-1571-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
199 Vietti Violi N, Duran R, Guiu B, Cercueil J, Aubé C, Digklia A, Pache I, Deltenre P, Knebel J, Denys A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. The Lancet Gastroenterology & Hepatology 2018;3:317-25. [DOI: 10.1016/s2468-1253(18)30029-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 30] [Article Influence: 29.0] [Reference Citation Analysis]
200 Kanda T, Jiang X, Yokosuka O. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World J Gastroenterol 2014; 20(28): 9229-9236 [PMID: 25071315 DOI: 10.3748/wjg.v20.i28.9229] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
201 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 148] [Article Influence: 38.8] [Reference Citation Analysis]
202 Jiang K, Zhang W, Su M, Liu Y, Zhao X, Wang J, Yao M, Ogbonna J, Dong J, Huang Z. Laparoscopic radiofrequency ablation of solitary small hepatocellular carcinoma in the caudate lobe. European Journal of Surgical Oncology (EJSO) 2013;39:1236-42. [DOI: 10.1016/j.ejso.2013.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
203 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [DOI: 10.3748/wjg.v27.i43.7462] [Reference Citation Analysis]
204 Ogasawara S, Chiba T, Motoyama T, Kanogawa N, Saito T, Shinozaki Y, Suzuki E, Ooka Y, Tawada A, Kato H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O. Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0163119. [PMID: 27649084 DOI: 10.1371/journal.pone.0163119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
205 Sato M, Tateishi R, Yasunaga H, Matsui H, Horiguchi H, Fushimi K, Koike K. Mortality and hemorrhagic complications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: A nationwide survey. J Gastroenterol Hepatol. 2017;32:1873-1878. [PMID: 28266772 DOI: 10.1111/jgh.13780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
206 Fujiwara N, Tateishi R, Kondo M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Masuzaki R, Nakagawa H. Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. Eur J Gastroenterol Hepatol. 2014;26:1039-1046. [PMID: 25051219 DOI: 10.1097/meg.0000000000000161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 42.5] [Reference Citation Analysis]
208 Ippolito D, Bonaffini PA, Capraro C, Leni D, Corso R, Sironi S. Viable residual tumor tissue after radiofrequency ablation treatment in hepatocellular carcinoma: evaluation with CT perfusion. Abdom Imaging. 2013;38:502-510. [PMID: 22743839 DOI: 10.1007/s00261-012-9924-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
209 Ishikawa T. Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(37): 6127-6130 [PMID: 24115808 DOI: 10.3748/wjg.v19.i37.6127] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
210 Kamarajah SK, Robinson D, Littler P, White SA. Small, incidental hepatic epithelioid haemangioendothelioma the role of ablative therapy in borderline patients. J Surg Case Rep. 2018;2018:rjy223. [PMID: 30151113 DOI: 10.1093/jscr/rjy223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
211 Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842 [PMID: 26207165 DOI: 10.4254/wjh.v7.i14.1834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
212 Thng CB, Tan YP, Shelat VG. Gas-forming pyogenic liver abscess: A world review. Ann Hepatobiliary Pancreat Surg 2018;22:11-8. [PMID: 29536051 DOI: 10.14701/ahbps.2018.22.1.11] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
213 Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2019;11:E1206. [PMID: 31430945 DOI: 10.3390/cancers11081206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
214 Takeyama N, Mizobuchi N, Sakaki M, Shimozuma Y, Munechika J, Kajiwara A, Uchikoshi M, Uozumi S, Ohgiya Y, Gokan T. Evaluation of hepatocellular carcinoma ablative margins using fused pre- and post-ablation hepatobiliary phase images. Abdom Radiol 2019;44:923-35. [DOI: 10.1007/s00261-018-1800-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
215 Imai K, Takai K, Maeda T, Watanabe S, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment. Oncotarget 2018;9:14058-67. [PMID: 29581826 DOI: 10.18632/oncotarget.24500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
216 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2013;48:951-65. [PMID: 23065022 DOI: 10.1007/s00535-012-0690-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
217 Fang KC, Su CW, Chiou YY, Lee PC, Chiu NC, Liu CA, Chen PH, Kao WY, Huang YH, Huo TI, Hou MC, Lin HC, Wu JC. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. Eur Radiol. 2017;27:2600-2609. [PMID: 27678133 DOI: 10.1007/s00330-016-4604-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
218 Hao Y, Numata K, Ishii T, Fukuda H, Maeda S, Nakano M, Tanaka K. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. World J Gastroenterol 2017; 23(17): 3111-3121 [PMID: 28533668 DOI: 10.3748/wjg.v23.i17.3111] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
219 Aigner F, Pratschke J, Schmelzle M. Oligometastatic Disease in Colorectal Cancer - How to Proceed?Visc Med. 2017;33:23-28. [PMID: 28612013 DOI: 10.1159/000454688] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
220 Ei S, Hibi T, Tanabe M, Itano O, Shinoda M, Kitago M, Abe Y, Yagi H, Okabayashi K, Sugiyama D, Wakabayashi G, Kitagawa Y. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol. 2015;22:1294-1300. [PMID: 25287439 DOI: 10.1245/s10434-014-4114-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
221 Lin CC, Lui KW, Chen WT, Hsieh YC, Cheng YT, Teng W, Lin SM. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. Eur Radiol 2021. [PMID: 33895858 DOI: 10.1007/s00330-021-07729-9] [Reference Citation Analysis]
222 Lewis AR, Padula CA, McKinney JM, Toskich BB. Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions. Semin Intervent Radiol 2019;36:303-9. [PMID: 31680721 DOI: 10.1055/s-0039-1697641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Nakajima K, Yamanaka T, Nakatsuka A, Haruyuki T, Fujimori M, Sugino Y, Matsushita N, Sakuma H, Isaji S, Takei Y, Yamakado K. Clinical utility of radiofrequency ablation following transarterial injection of miriplatin-iodized oil suspension in small hepatocellular carcinoma. Jpn J Radiol 2016;34:640-6. [PMID: 27455985 DOI: 10.1007/s11604-016-0567-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
224 Chen P, Kao W, Chiou Y, Hung H, Su C, Chou Y, Huo T, Huang Y, Wu W, Chao Y, Lin H, Wu J. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology 2013;12:263-73. [DOI: 10.1016/s1665-2681(19)31365-1] [Cited by in Crossref: 15] [Article Influence: 1.9] [Reference Citation Analysis]
225 Takai Takamatsu R, Okano A, Yamakawa G, Mizukoshi K, Obayashi H, Ohana M. Impact of an ultrasound-guided radiofrequency ablation training program on the outcomes in patients with hepatocellular carcinoma. Diagn Interv Imaging 2019;100:771-80. [PMID: 31477516 DOI: 10.1016/j.diii.2019.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
226 Schwartz M, Florman S. Optimal liver allocation for hepatocellular carcinoma: hurry up AND wait, but which one when? Am J Transplant 2014;14:1479-80. [PMID: 24903890 DOI: 10.1111/ajt.12773] [Reference Citation Analysis]
227 Han J, Fan YC, Wang K. Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22703. [PMID: 33120763 DOI: 10.1097/MD.0000000000022703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
228 Ding J, Jing X, Wang Y, Wang F, Wang Y, Du Z. Thermal ablation for hepatocellular carcinoma: a large-scale analysis of long-term outcome and prognostic factors. Clinical Radiology 2016;71:1270-6. [DOI: 10.1016/j.crad.2016.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
229 Lee DH, Lee JM, Kim PN, Jang YJ, Kang TW, Rhim H, Seo JW, Lee YJ. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. Eur Radiol 2019;29:5052-62. [PMID: 30770968 DOI: 10.1007/s00330-018-5993-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
230 Yang W, Ziemlewicz TJ, Varghese T, Alexander ML, Rubert N, Ingle AN, Lubner MG, Hinshaw JL, Wells SA, Lee FT Jr, Zagzebski JA. Post-Procedure Evaluation of Microwave Ablations of Hepatocellular Carcinomas Using Electrode Displacement Elastography. Ultrasound Med Biol 2016;42:2893-902. [PMID: 27592561 DOI: 10.1016/j.ultrasmedbio.2016.07.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
231 Liu X, Hou Y, Wang X, Yu L, Wang X, Jiang L, Yang Z. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int 2020;14:567-76. [DOI: 10.1007/s12072-020-10046-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
232 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma. Japanese Journal of Clinical Oncology 2020;50:36-43. [DOI: 10.1093/jjco/hyz129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
233 Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019;156:1683-1692.e1. [PMID: 30660729 DOI: 10.1053/j.gastro.2019.01.027] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 33.0] [Reference Citation Analysis]
234 El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J 2017;5:227-35. [PMID: 28344790 DOI: 10.1177/2050640616659024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
235 Ganne-Carrié N, Nault JC, Ziol M, N'Kontchou G, Nahon P, Grando V, Bourcier V, Barge S, Beaugrand M, Trinchet JC, Seror O. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma. Hepat Oncol 2014;1:395-408. [PMID: 30190975 DOI: 10.2217/hep.14.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
236 Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. Hepatol Res 2018;48:E61-7. [PMID: 28628718 DOI: 10.1111/hepr.12927] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
237 Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, Kim YJ, Han JK, Choi BI. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270:900-909. [PMID: 24475823 DOI: 10.1148/radiol.13130940] [Cited by in Crossref: 155] [Cited by in F6Publishing: 151] [Article Influence: 19.4] [Reference Citation Analysis]
238 Tan Y, Jiang J, Wang Q, Guo S, Ma K, Bie P. Radiofrequency ablation using a multiple-electrode switching system for hepatocellular carcinoma within the Milan criteria: long-term results. International Journal of Hyperthermia 2018;34:298-305. [DOI: 10.1080/02656736.2017.1330495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
239 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
240 Zhang YH, Su B, Sun P, Li RM, Peng XC, Cai J. Percutaneous radiofrequency ablation is superior to hepatic resection in patients with small hepatocellular carcinoma. World J Clin Cases 2020; 8(19): 4380-4387 [PMID: 33083397 DOI: 10.12998/wjcc.v8.i19.4380] [Reference Citation Analysis]
241 Xuan M, Zhou F, Ding Y, Zhu Q, Dong J, Zhou H, Cheng J, Jiang X, Wu P. Diagnostic accuracy of contrast-enhanced ultrasound in assessing the therapeutic response to radio frequency ablation for liver tumors: systematic review and meta-analysis. Surg Endosc 2018;32:2067-75. [DOI: 10.1007/s00464-017-5903-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
242 Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial. Am J Gastroenterol. 2013;108:1305-1313. [PMID: 23629602 DOI: 10.1038/ajg.2013.109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
243 Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015; 7(11): 1521-1529 [PMID: 26085911 DOI: 10.4254/wjh.v7.i11.1521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
244 Hirai T, Shinoda Y, Tateishi R, Asaoka Y, Uchino K, Wake T, Kobayashi H, Ikegami M, Sawada R, Haga N, Koike K, Tanaka S. Early detection of bone metastases of hepatocellular carcinoma reduces bone fracture and paralysis. Japanese Journal of Clinical Oncology 2019;49:529-36. [DOI: 10.1093/jjco/hyz028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
245 Hong HP, Lee JY, Lee MY, Jung KU, Kim BI, Son BH, Shin JH, Lee SR. Early experience with laparoscopic treatment of liver tumors using a separable cluster electrode with a no-touch technique. Wideochir Inne Tech Maloinwazyjne 2021;16:76-82. [PMID: 33786119 DOI: 10.5114/wiitm.2020.95065] [Reference Citation Analysis]
246 Ippolito D, Fior D, Bonaffini PA, Capraro C, Leni D, Corso R, Sironi S. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol. 2014;83:1665-1671. [PMID: 24962900 DOI: 10.1016/j.ejrad.2014.05.040] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
247 Cho JY, Choi MS, Lee GS, Sohn W, Ahn J, Sinn DH, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clin Mol Hepatol 2016;22:477-86. [PMID: 28081587 DOI: 10.3350/cmh.2016.0048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
248 Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology. 2013;58:1655-1666. [PMID: 23703789 DOI: 10.1002/hep.26487] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
249 Li SY, Huang PT, Fang Y, Wu Y, Zhou L, Luo JL, Wang XC, Chen YC. Ultrasonic Cavitation Ameliorates Antitumor Efficacy of Residual Cancer After Incomplete Radiofrequency Ablation in Rabbit VX2 Liver Tumor Model. Transl Oncol 2019;12:1113-21. [PMID: 31176089 DOI: 10.1016/j.tranon.2019.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
250 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
251 Sarpel U, Spivack JH, Berger Y, Heskel M, Aycart SN, Sweeney R, Edwards MP, Labow DM, Kim E. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. HPB (Oxford) 2016;18:411-8. [PMID: 27154804 DOI: 10.1016/j.hpb.2016.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
252 Kuo Y, Chung K, Hung C, Lu S, Wang J. The impact of general anesthesia on radiofrequency ablation of hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences 2014;30:559-65. [DOI: 10.1016/j.kjms.2014.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
253 Lee DH, Lee JM, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK. Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. Liver Cancer. 2018;7:65-75. [PMID: 29662834 DOI: 10.1159/000484445] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
254 Pohlman RM, Hinshaw JL, Ziemlewicz TJ, Lubner MG, Wells SA, Lee FT Jr, Alexander ML, Wergin KL, Varghese T. Differential Imaging of Liver Tumors before and after Microwave Ablation with Electrode Displacement Elastography. Ultrasound Med Biol 2021;47:2138-56. [PMID: 34011451 DOI: 10.1016/j.ultrasmedbio.2021.03.027] [Reference Citation Analysis]
255 Morimoto N, Isoda N, Watanabe S, Otake T, Hirosawa T, Tsukui M, Miyata N, Murayama K, Iwashita C, Takaoka Y, Yamamoto H. A case of small hepatocellular carcinoma treated with laparoscopic multipolar radiofrequency ablation with a no-touch ablation procedure. Clin J Gastroenterol 2014;7:510-5. [PMID: 25491908 DOI: 10.1007/s12328-014-0531-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
256 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
257 Yamakado K, Takaki H, Nakatsuka A, Yamaknaka T, Fujimori M, Hasegawa T, Uraki J. Radiofrequency ablation for hepatocellular carcinoma. Gastrointestinal Intervention 2014;3:35-9. [DOI: 10.1016/j.gii.2014.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
258 Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, Mcwilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DS. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology 2017;65:1979-90. [DOI: 10.1002/hep.29098] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]
259 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
260 Virarkar M, Saleh M, Diab R, Taggart M, Bhargava P, Bhosale P. Hepatic Hemangioendothelioma: An update. World J Gastrointest Oncol 2020; 12(3): 248-266 [PMID: 32206176 DOI: 10.4251/wjgo.v12.i3.248] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
261 Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2018;129:44-53. [DOI: 10.1016/j.critrevonc.2018.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
262 Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist 2019;24:e990-e1005. [PMID: 31217342 DOI: 10.1634/theoncologist.2018-0337] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 37.5] [Reference Citation Analysis]
263 Kim S, Kang T, Kim M, Lee M, Cho S, Paik Y, Kim M. Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation. Clinical Radiology 2018;73:216.e1-8. [DOI: 10.1016/j.crad.2017.07.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
264 Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. Int J Mol Sci 2019;20:E605. [PMID: 30704150 DOI: 10.3390/ijms20030605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
265 Kariyama K, Nouso K, Wakuta A, Oonishi A, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. Liver Cancer 2020;9:41-9. [PMID: 32071908 DOI: 10.1159/000502479] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
266 Uchino K, Tateishi R, Nakagomi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shibahara J, Shiina S, Koike K. Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One 2018;13:e0200943. [PMID: 30044835 DOI: 10.1371/journal.pone.0200943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
267 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
268 Zhang M, Zhang S, Yang Z, Hu J, Hu W, Sun P, Wu L, Han B. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence. Oncol Lett 2018;16:7158-65. [PMID: 30546452 DOI: 10.3892/ol.2018.9557] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
269 Wang D, Zheng X, Fu B, Nian Z, Qian Y, Sun R, Tian Z, Wei H. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling. EBioMedicine 2019;46:119-32. [PMID: 31375423 DOI: 10.1016/j.ebiom.2019.07.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
270 Zhang N, Li H, Qin C, Ma D, Zhao Y, Zhu W, Wang L. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol 2019;145:895-907. [PMID: 30820716 DOI: 10.1007/s00432-019-02852-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
271 Ishikawa T, Kubota T, Abe S, Watanabe Y, Sugano T, Inoue R, Iwanaga A, Seki K, Honma T, Yoshida T. Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival. Ann Oncol. 2014;25:1379-1384. [PMID: 24737779 DOI: 10.1093/annonc/mdu155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
272 Chen HY, Lu SN, Hung CH, Wang JH, Chen CH, Yen YH, Kuo YH, Kee KM. Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. PLoS One 2020;15:e0242113. [PMID: 33170894 DOI: 10.1371/journal.pone.0242113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
273 Lee T, Lin J, Ho HJ, Wu M, Wu C. Evaluation of the Effect of Cumulative Operator Experience on Hepatocellular Carcinoma Recurrence after Primary Treatment with Radiofrequency Ablation. Radiology 2015;276:294-301. [DOI: 10.1148/radiol.15141864] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
274 Lee DH, Lee MW, Kim PN, Lee YJ, Park HS, Lee JM. Outcome of No-Touch Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Multicenter Clinical Trial. Radiology 2021;:210309. [PMID: 34313474 DOI: 10.1148/radiol.2021210309] [Reference Citation Analysis]
275 Pang Q, Qu K, Zhang JY, Song SD, Liu SS, Tai MH, Liu HC, Liu C. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015;94:e1431. [PMID: 26376382 DOI: 10.1097/MD.0000000000001431] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
276 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology 2021;74:603-12. [DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
277 Huang J, Huang W, Guo Y, Cai M, Zhou J, Lin L, Zhu K. Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma. Front Oncol 2021;11:638428. [PMID: 34123790 DOI: 10.3389/fonc.2021.638428] [Reference Citation Analysis]
278 Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, Shiina S, Fontana A, Torzilli G. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016;6:34-43. [PMID: 27995086 DOI: 10.1159/000449346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
279 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
280 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2014;44:608-620. [PMID: 23701455 DOI: 10.1111/hepr.12169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
281 Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, Takayama H, Abe T, Sato K, Kakizaki S. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study. Hepatol Res. 2018;48:165-175. [PMID: 28500686 DOI: 10.1111/hepr.12912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
282 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
283 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One 2014;9:e99115. [PMID: 24906132 DOI: 10.1371/journal.pone.0099115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
284 Nuta J, Tamai H, Mori Y, Shingaki N, Maeshima S, Shimizu R, Maeda Y, Moribata K, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Kupffer Imaging by Contrast-Enhanced Sonography With Perfluorobutane Microbubbles Is Associated With Outcomes After Radiofrequency Ablation of Hepatocellular Carcinoma. Journal of Ultrasound in Medicine 2016;35:359-71. [DOI: 10.7863/ultra.15.04067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
285 Ma S, Ding M, Li J, Wang T, Qi X, Shi Y, Ming Y, Chi J, Wang Z, Tang X, Cui D, Zhang Y, Zhai B. Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors. J Cancer Res Clin Oncol 2017;143:131-42. [DOI: 10.1007/s00432-016-2266-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
286 Lin SM. Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer 2013;2:73-83. [PMID: 24159599 DOI: 10.1159/000343843] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
287 Choi JW, Lee JM, Lee DH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Cho EJ. Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. Korean J Radiol 2021;22:179-88. [PMID: 32729269 DOI: 10.3348/kjr.2020.0134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
288 Su Z, Li K, Xu E, Wu L, Wang X, Li L, Wang J, Lin P, Chen Y, Zhang Y, Li J, Dufour C, Mory B, Zheng R. A clinical validation study for the feasibility and reliability of three-dimensional ultrasound-ultrasound automatic image registration. International Journal of Hyperthermia 2015;31:875-82. [DOI: 10.3109/02656736.2015.1073370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
289 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
290 Endo K, Kuroda H, Oikawa T, Okada Y, Fujiwara Y, Abe T, Sato H, Sawara K, Takikawa Y. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018;53:1575-83. [PMID: 30577723 DOI: 10.1080/00365521.2018.1548645] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
291 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
292 Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2016;63:1517-1527. [PMID: 26426978 DOI: 10.1002/hep.28266] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
293 Woo JH, Song KD, Kim SH. Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Outcomes of early treatment and watchful waiting. Eur Radiol. 2017;27:4406-4414. [PMID: 28386720 DOI: 10.1007/s00330-017-4818-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
294 Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH, Kim BW, Kim SS, Noh CK, Shin SJ, Lee KM, Cho SW, Cheong JY. High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clinical Biochemistry 2015;48:1073-8. [DOI: 10.1016/j.clinbiochem.2015.06.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
295 Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther 2016; 7(4): 477-489 [PMID: 27867681 DOI: 10.4292/wjgpt.v7.i4.477] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 63] [Article Influence: 13.4] [Reference Citation Analysis]
296 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
297 Kanogawa N, Ogasawara S, Ooka Y, Inoue M, Wakamatsu T, Yokoyama M, Maruta S, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Maeda T, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Saito T, Motoyama T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Takemura R, Nozaki-Taguchi N, Shiroh I, Yokosuka O, Kato N. Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open 2021;5:273-9. [PMID: 33553667 DOI: 10.1002/jgh3.12483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15. [PMID: 32646200 DOI: 10.3350/cmh.2020.0038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
299 Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014;5:221-230. [PMID: 24665346 DOI: 10.7150/jca.7691] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
300 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
301 Nishigaki Y, Hayashi H, Tomita E, Suzuki Y, Watanabe N, Watanabe S, Watanabe C, Takagi Y, Kato T, Naiki T. Usefulness of contrast-enhanced ultrasonography using Sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma: CEUS assessment of therapeutic effect of PRFA. Hepatol Res 2015;45:432-40. [DOI: 10.1111/hepr.12370] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
302 Zhang B, Moser MA, Luo Y, Zhang EM, Zhang W. Evaluation of the current radiofrequency ablation systems using axiomatic design theory. Proc Inst Mech Eng H 2014;228:397-408. [PMID: 24705341 DOI: 10.1177/0954411914530104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
303 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol 2015; 7(15): 1913-1920 [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
304 Paul S, Acharya S, Gamanagatti S, Sreenivas V, Shalimar S, Gulati M. Acetic acid versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A randomized controlled trial. Diagnostic and Interventional Imaging 2020;101:101-10. [DOI: 10.1016/j.diii.2019.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
305 Liu PH, Hsu CY, Lee YH, Su CW, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) 2015;94:e1772. [PMID: 26469917 DOI: 10.1097/MD.0000000000001772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
306 Shinohara K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Shimoyama Y, Shiina S, Tateishi R, Arano T, Nagino M. Successful local treatment for repeated hepatic recurrences of cholangiolocellular carcinoma: a report on a long-term survivor. Surg Case Rep 2017;3:120. [PMID: 29198012 DOI: 10.1186/s40792-017-0391-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
307 Yamagishi S, Midorikawa Y, Nakayama H, Higaki T, Moriguchi M, Aramaki O, Yamazaki S, Tsuji S, Takayama T. Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Hepatol Res 2018;49:432-40. [DOI: 10.1111/hepr.13293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
308 Cui X, Wu Y, Wang Z, Liu X, Wang S, Qin C. MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Tumour Biol. 2015;36:3887-3893. [PMID: 25596083 DOI: 10.1007/s13277-014-3031-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
309 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
310 Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8:250. [PMID: 24160944 DOI: 10.1186/1748-717x-8-250] [Cited by in Crossref: 124] [Cited by in F6Publishing: 56] [Article Influence: 15.5] [Reference Citation Analysis]
311 D'Onofrio M, Cardobi N, Ruzzenente A, Conci S, Ciaravino V, Guglielmi A, Mucelli RP. Unenhanced magnetic resonance imaging immediately after radiofrequency ablation of liver malignancy: preliminary results. Abdom Radiol (NY) 2018;43:1379-85. [PMID: 28861631 DOI: 10.1007/s00261-017-1299-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016;370:78-84. [PMID: 26472630 DOI: 10.1016/j.canlet.2015.09.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
313 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
314 Bang A, Dawson LA. Radiotherapy for HCC: Ready for prime time? JHEP Rep 2019;1:131-7. [PMID: 32039361 DOI: 10.1016/j.jhepr.2019.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
315 Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Shiraki K, Takei Y, Sakuma H, Yamakado K. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 2013;24:655-66. [PMID: 23428356 DOI: 10.1016/j.jvir.2012.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
316 Park HJ, Lee MW, Rhim H, Cha DI, Kang TW, Lim S, Song KD, Lim HK. Percutaneous ultrasonography-guided radiofrequency ablation of hepatocellular carcinomas: usefulness of image fusion with three-dimensional ultrasonography. Clin Radiol. 2015;70:387-394. [PMID: 25582889 DOI: 10.1016/j.crad.2014.12.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
317 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R, Kay CS, Heo SJ, Won JY, Seong J. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73:121-129. [PMID: 32165253 DOI: 10.1016/j.jhep.2020.03.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 37.0] [Reference Citation Analysis]
319 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
320 Zhu L, Zhao Y, Yu L, He X, Wang Y, Jiang P, Yu R, Li W, Dong B, Wang X, Dong Y. Overexpression of ADAM9 decreases radiosensitivity of hepatocellular carcinoma cell by activating autophagy. Bioengineered 2021;12:5516-28. [PMID: 34528498 DOI: 10.1080/21655979.2021.1965694] [Reference Citation Analysis]
321 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open 2021;6:100170. [PMID: 34090171 DOI: 10.1016/j.esmoop.2021.100170] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Burgmans MC, Too CW, Fiocco M, Kerbert AJ, Lo RH, Schaapman JJ, van Erkel AR, Coenraad MJ, Tan BS. Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2016;39:1708-15. [PMID: 27671151 DOI: 10.1007/s00270-016-1462-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
324 Salman A, Salman M, Moustafa A, Shaaban HE, El-Mikkawy A, Labib S, Youssef A, Omar MG, Matter M, Elkassar H. Impact of Sarcopenia on Two-Year Mortality in Patients with HCV-Associated Hepatocellular Carcinoma After Radiofrequency Ablation. J Hepatocell Carcinoma 2021;8:313-20. [PMID: 33954153 DOI: 10.2147/JHC.S300680] [Reference Citation Analysis]
325 Mironov O, Jaberi A, Kachura JR. Thermal Ablation versus Surgical Resection for the Treatment of Stage T1 Hepatocellular Carcinoma in the Surveillance, Epidemiology, and End Results Database Population. Journal of Vascular and Interventional Radiology 2017;28:325-33. [DOI: 10.1016/j.jvir.2016.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
326 Preel A, Hermida M, Allimant C, Assenat E, Guillot C, Gozzo C, Aho-Glele S, Pageaux GP, Cassinotto C, Guiu B. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers (Basel) 2021;13:2700. [PMID: 34070800 DOI: 10.3390/cancers13112700] [Reference Citation Analysis]
327 Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48:127-137. [PMID: 29851093 DOI: 10.1111/apt.14823] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
328 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
329 Kato K, Abe H, Ika M, Yonezawa T, Sato Y, Hanawa N, Shimizu S, Endo S, Matsuo R, Tsubota A. C-Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma. Oncology. 2017;92:142-152. [PMID: 28052301 DOI: 10.1159/000453665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
330 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0161303. [PMID: 27537374 DOI: 10.1371/journal.pone.0161303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
331 付雪丹, 刘彦丽. 超声引导下PRFA治疗非手术适应症肝癌术后的肿瘤影像表现与疗效的关系. 世界华人消化杂志 2013; 21(33): 3747-3751 [DOI: 10.11569/wcjd.v21.i33.3747] [Reference Citation Analysis]
332 Su M, Zhao Y, Liu J. The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study. Medicine (Baltimore) 2018;97:e0020. [PMID: 29517658 DOI: 10.1097/MD.0000000000010020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
333 Lee WC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM. Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2019;9:2269. [PMID: 30783140 DOI: 10.1038/s41598-019-38785-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
334 Lin JW, Lin CC, Chen WT, Lin SM. Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma (3.1-4 cm) and in high-risk locations. Kaohsiung J Med Sci 2014;30:396-401. [PMID: 25002377 DOI: 10.1016/j.kjms.2014.04.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
335 Yamada T, Tateishi R, Iwai M, Koike K, Todo T. Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation. Mol Ther Oncolytics 2020;18:535-45. [PMID: 32995479 DOI: 10.1016/j.omto.2020.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
336 Lee SH, Kim SU, Jang JW, Bae SH, Lee S, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. Onco Targets Ther 2015;8:347-56. [PMID: 25678801 DOI: 10.2147/OTT.S75077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
337 Hsu CY, Liu PH, Ho SY, Hsia CY, Kudaravalli P, Lee YH, Chiou YY, Tsai YJ, Huang YH, Huo TI. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289. [PMID: 29540157 DOI: 10.1186/s12885-018-4202-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
338 Inoue M, Ogasawara S, Chiba T, Ooka Y, Wakamatsu T, Kobayashi K, Suzuki E, Tawada A, Yokosuka O. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:908-15. [PMID: 27787908 DOI: 10.1111/jgh.13622] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
339 Yamazaki H, Tsuji K, Nagai K, Tomonari A, Matsui T, Kang J, Kodama Y, Sakurai Y, Maguchi H. Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma: RFA in the elderly with HCC. Hepatol Res 2014;44:1095-101. [DOI: 10.1111/hepr.12233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
340 Wakamatsu T, Ogasawara S, Chiba T, Yokoyama M, Inoue M, Kanogawa N, Saito T, Suzuki E, Ooka Y, Tawada A, Yokosuka O. Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. PLoS One 2017;12:e0170153. [PMID: 28099460 DOI: 10.1371/journal.pone.0170153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
341 Hiraoka A, Nagamatsu K, Izumoto H, Adachi T, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Suga Y, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K. Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. Hepatol Res 2020;50:92-100. [PMID: 31729124 DOI: 10.1111/hepr.13430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
342 Kairaluoma V, Karjalainen M, Pohjanen VM, Saarnio J, Niemelä J, Huhta H, Helminen O. Treatment trends and outcomes of hepatocellular carcinoma in a single center for 35 years. Minerva Surg 2021;76:252-63. [PMID: 33890436 DOI: 10.23736/S2724-5691.21.08426-1] [Reference Citation Analysis]
343 Liu X, Jing X, Cheng X, Ma D, Jin Z, Yang W, Qiu W. FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation. Med Oncol 2016;33:46. [PMID: 27044356 DOI: 10.1007/s12032-016-0761-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
344 Kang TW, Kim JM, Rhim H, Lee MW, Kim YS, Lim HK, Choi D, Song KD, Kwon CH, Joh JW, Paik SW, Paik YH, Ahn JH. Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes. Radiology. 2015;275:908-919. [PMID: 25688888 DOI: 10.1148/radiol.15141483] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
345 Takada H, Tsuchiya K, Yasui Y, Nakakuki N, Tamaki N, Suzuki S, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Izumi N. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med 2016;5:3111-20. [PMID: 27748052 DOI: 10.1002/cam4.932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
346 Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy: NAGAOKI et al.. J Med Virol 2019;91:650-8. [DOI: 10.1002/jmv.25352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
347 Yao XS, Yan D, Jiang XX, Li X, Zeng HY, Li H. Short-term outcomes of radiofrequency ablation for hepatocellular carcinoma using cone-beam computed tomography for planning and image guidance. World J Clin Cases 2021; 9(7): 1580-1591 [PMID: 33728301 DOI: 10.12998/wjcc.v9.i7.1580] [Reference Citation Analysis]
348 Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open 2021;5:705-11. [PMID: 34124389 DOI: 10.1002/jgh3.12573] [Reference Citation Analysis]
349 Kim N, Seong J. What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma? JCO 2018;36:2560-1. [DOI: 10.1200/jco.2018.78.1740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
350 Fujiwara N, Tateishi R, Akahane M, Taguri M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Ohtomo K, Koike K. Changes in risk of immediate adverse reactions to iodinated contrast media by repeated administrations in patients with hepatocellular carcinoma. PLoS One 2013;8:e76018. [PMID: 24098420 DOI: 10.1371/journal.pone.0076018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
351 Zhang N, Zhu H, Dong YH, Wang L. Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer. Oncol Lett 2019;18:2548-53. [PMID: 31402950 DOI: 10.3892/ol.2019.10552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
352 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
353 Gonoi W, Hayashi TY, Okuma H, Akahane M, Nakai Y, Mizuno S, Tateishi R, Isayama H, Koike K, Ohtomo K. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case–cohort study. Eur Radiol 2017;27:4941-50. [DOI: 10.1007/s00330-017-4895-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
354 Zhang N, Wang L, Chai ZT, Zhu ZM, Zhu XD, Ma DN, Zhang QB, Zhao YM, Wang M, Ao JY, Ren ZG, Gao DM, Sun HC, Tang ZY. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One 2014;9:e115949. [PMID: 25542041 DOI: 10.1371/journal.pone.0115949] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
355 Molina V, Sampson-Dávila J, Ferrer J, Fondevila C, Díaz Del Gobbo R, Calatayud D, Bruix J, García-Valdecasas JC, Fuster J. Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. Surg Endosc 2018;32:2345-54. [PMID: 29218665 DOI: 10.1007/s00464-017-5930-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
356 Hu XY, Li L, Wu HT, Liu Y, Wang BD, Tang Y. Serum miR-130b level, an ideal marker for monitoring the recurrence and prognosis of primary hepatocellular carcinoma after radiofrequency ablation treatment. Pathol Res Pract 2018;214:1655-60. [PMID: 30153957 DOI: 10.1016/j.prp.2018.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
357 Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, Chen SL, Chiu SY, Fann JC, Su WW, Fang YJ. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59:1840-1849. [PMID: 24002724 DOI: 10.1002/hep.26703] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
358 Azumi M, Suda T, Terai S, Akazawa K. Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study. Intern Med 2017;56:1001-7. [PMID: 28458303 DOI: 10.2169/internalmedicine.56.7278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
359 Ochi H, Hirooka M, Hiraoka A, Koizumi Y, Abe M, Sogabe I, Ishimaru Y, Furuya K, Miyagawa M, Kawasaki H, Michitaka K, Takada Y, Mochizuki T, Hiasa Y. 18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma. Mol Clin Oncol. 2014;2:798-804. [PMID: 25054048 DOI: 10.3892/mco.2014.328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
360 Niemeyer DJ, Simo KA, Iannitti DA, McKillop IH. Ablation therapy for hepatocellular carcinoma: past, present and future perspectives. Hepat Oncol 2014;1:67-79. [PMID: 30190942 DOI: 10.2217/hep.13.8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
361 Xu E, Li K, Long Y, Luo L, Zeng Q, Tan L, He X, Huang Q, Wu Y, Zheng R. Intra-Procedural CT/MR-Ultrasound Fusion Imaging Helps to Improve Outcomes of Thermal Ablation for Hepatocellular Carcinoma: Results in 502 Nodules. Ultraschall Med 2021;42:e9-e19. [PMID: 31671457 DOI: 10.1055/a-1021-1616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
362 Morishita A, Sakamoto T, Kobara H, Tadokoro T, Ohura K, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T, Masaki T. Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver. Mol Clin Oncol 2016;4:183-6. [PMID: 26893857 DOI: 10.3892/mco.2015.680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
363 Cheung TT, Ma KW, She WH. A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis. Hepatobiliary Surg Nutr 2021;10:193-209. [PMID: 33898560 DOI: 10.21037/hbsn.2020.03.11] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Gonoi W, Okuma H, Hayashi TY, Akahane M, Nakai Y, Tateishi R, Mizuno S, Suzuki Y, Mitsuda M, Matsuda K, Nakagawa K, Isayama H, Miyagawa K, Koike K, Abe O. Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study. Saudi J Gastroenterol 2019;25:390-6. [PMID: 31274472 DOI: 10.4103/sjg.SJG_56_19] [Reference Citation Analysis]
365 Bouda D, Barrau V, Raynaud L, Dioguardi Burgio M, Paulatto L, Roche V, Sibert A, Moussa N, Vilgrain V, Ronot M. Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis. Cardiovasc Intervent Radiol 2020;43:1608-18. [PMID: 32533309 DOI: 10.1007/s00270-020-02549-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
366 Kim SM, Shin SS, Lee BC, Kim JW, Heo SH, Lim HS, Jeong YY. Imaging evaluation of ablative margin and index tumor immediately after radiofrequency ablation for hepatocellular carcinoma: comparison between multidetector-row CT and MR imaging. Abdom Radiol 2017;42:2527-37. [DOI: 10.1007/s00261-017-1146-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
367 Espinosa W, Liu YW, Wang CC, Lin CC, Wang JH, Lu SN, Hung CH. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. J Formos Med Assoc 2018;117:197-203. [PMID: 28411877 DOI: 10.1016/j.jfma.2017.03.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
368 Ettorre GM, Laurenzi A. Other “Bridge” Therapies for Liver Transplantation: RFA, TACE, and TARE. In: Cillo U, De Carlis L, editors. Liver Transplantation and Hepatobiliary Surgery. Cham: Springer International Publishing; 2020. pp. 183-91. [DOI: 10.1007/978-3-030-19762-9_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, Grando V, Blaise L, Ziol M, Nahon P, Ganne‐carrié N, Sutter O, Seror O, Nault J. Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. Journal of Gastroenterology and Hepatology 2019;35:142-50. [DOI: 10.1111/jgh.14763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
370 Santambrogio R, Bruno S, Kluger MD, Costa M, Salceda J, Belli A, Laurent A, Barabino M, Opocher E, Azoulay D, Cherqui D. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma. Digestive and Liver Disease 2016;48:189-96. [DOI: 10.1016/j.dld.2015.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
371 Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012;47:1152-1159. [PMID: 22438097 DOI: 10.1007/s00535-012-0574-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
372 Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89-97. [PMID: 23023009 DOI: 10.1016/j.jhep.2012.09.020] [Cited by in Crossref: 209] [Cited by in F6Publishing: 193] [Article Influence: 23.2] [Reference Citation Analysis]
373 Di Costanzo GG, Signoriello S, Tortora R, Gallo C. A prognostic index for patients within the intermediate stage of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2016;28:592-8. [DOI: 10.1097/meg.0000000000000562] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
374 Wake T, Tateishi R, Nakagomi R, Fujiwara N, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Tanaka Y, Shiina S, Koike K. Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. Hepatol Res 2018;49:453-61. [DOI: 10.1111/hepr.13302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
375 Yamao T, Imai K, Yamashita Y, Kaida T, Nakagawa S, Mima K, Hashimoto D, Chikamoto A, Ishiko T, Baba H. Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation? HPB 2018;20:244-50. [DOI: 10.1016/j.hpb.2017.08.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
376 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013;4:473-80. [PMID: 23901347 DOI: 10.7150/jca.6609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
377 Song KD, Rhim H, Lee MW, Kim Y, Kang TW. Intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma: precursor nodules on pre-procedural gadoxetic acid-enhanced liver magnetic resonance imaging. Acta Radiol 2017;58:778-85. [DOI: 10.1177/0284185116673122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
378 Shimizu R, Tamai H, Mori Y, Shingaki N, Maeshima S, Nuta J, Maeda Y, Moribata K, Muraki Y, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. The arterial tumor enhancement pattern on contrast-enhanced computed tomography is associated with primary cancer death after radiofrequency ablation for small hepatocellular carcinoma. Hepatol Int 2016;10:328-39. [DOI: 10.1007/s12072-015-9678-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
379 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
380 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PMID: 25752327 DOI: 10.1111/liv.12818] [Cited by in Crossref: 369] [Cited by in F6Publishing: 382] [Article Influence: 61.5] [Reference Citation Analysis]
381 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
382 Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer 2019;8:121-9. [PMID: 31019902 DOI: 10.1159/000488778] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
383 Su XF, Li N, Chen XF, Zhang L, Yan M. Incidence and Risk Factors for Liver Abscess After Thermal Ablation of Liver Neoplasm. Hepat Mon 2016;16:e34588. [PMID: 27642345 DOI: 10.5812/hepatmon.34588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
384 Kanda T, Yokosuka O. The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:91-9. [PMID: 27508198 DOI: 10.2147/JHC.S48956] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
385 Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. Mol Clin Oncol. 2020;12:111-116. [PMID: 31929880 DOI: 10.3892/mco.2019.1956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
386 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
387 Shan W, Mao X, Wang X, Hogan RE, Wang Q. Potential surgical therapies for drug-resistant focal epilepsy. CNS Neurosci Ther 2021. [PMID: 34101365 DOI: 10.1111/cns.13690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]